ストックスクリーナーアプリを入手
1.43
2.05%
-0.03
アフターアワーズ：
1.43
前日終値:
$1.46
開ける：
$1.46
24時間の取引高:
2,521
Relative Volume:
0.08
時価総額：
$36.96M
収益：
-
当期純損益:
-
株価収益率:
-4.108
EPS:
-0.3481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+18.67%
1か月 パフォーマンス:
-2.05%
6か月 パフォーマンス:
-39.52%
1年 パフォーマンス:
+20.17%
1日の値動き範囲:
$1.43
$1.48
1週間の範囲:
$1.0301
$1.58
52週間の値動き範囲:
$0.85
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
名前
Akari Therapeutics Plc Adr
セクター
電話
(646) 350-0702
住所
22 BOSTON WHARF ROAD, BOSTON
AKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.43 | 36.96M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-01-04 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | アップグレード | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 繰り返されました | Chardan Capital Markets | Sell |
| 2016-07-11 | 開始されました | Chardan Capital Markets | Sell |
すべてを表示
Akari Therapeutics Plc Adr (AKTX) 最新ニュース
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com India
Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan
Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Growth in Short Interest - Defense World
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics names Samir Patel as CEO and adds board member - Investing.com India
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Akari Therapeutics appoints new CFO - Investing.com
Akari Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - StockTitan
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights - StockTitan
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering - StockTitan
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com Australia
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN
Akari Therapeutics Plc Adr (AKTX) 財務データ
Akari Therapeutics Plc Adr (AKTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):